Application-Specific R&D Capabilities and the Advantage of Incumbents: Evidence from the Anticancer Drug Market
暂无分享,去创建一个
[1] J. Schumpeter,et al. The Theory of Economic Development , 2017 .
[2] Cynthia A. Montgomery,et al. Diversification, Ricardian rents, and Tobin's q , 1988 .
[3] Elkan F Halpern,et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. , 2004, JAMA.
[4] T. Allen,et al. Decoupling market incumbency from organizational experience : a study of biotechnology's impact on the market for anti-cancer drugs , 2006 .
[5] Leslie E. Papke,et al. Econometric Methods for Fractional Response Variables with an Application to 401(K) Plan Participation Rates , 1993 .
[6] David C. Mowery,et al. Sources of Industrial Leadership , 1999 .
[7] Clayton M. Christensen. The Innovator's Dilemma , 1997 .
[8] W. S. Comanor,et al. Strategic Pricing of New Pharmaceuticals , 1998, Review of Economics and Statistics.
[9] Will Mitchell,et al. The Dynamics of Evolving Markets: The Effects of Business Sales and Age on Dissolutions and Divestitures , 1994 .
[10] Kathleen Reavis Conner,et al. Strategies for product cannibalism , 1988 .
[11] F. Rothaermel. Incumbent's advantage through exploiting complementary assets via interfirm cooperation , 2001 .
[12] Luigi Orsenigo,et al. The Emergence of Biotechnology: Institutions and Markets in Industrial Innovation , 1989 .
[13] G. Maddala. Limited-dependent and qualitative variables in econometrics: Introduction , 1983 .
[14] P. Schmidt,et al. Limited-Dependent and Qualitative Variables in Econometrics. , 1984 .
[15] R. Henderson. Of life cycles real and imaginary : the unexpectedly long old age of optical lithography , 1995 .
[16] Constance E. Helfat,et al. Know-how and asset complementarity and dynamic capability accumulation : The case of R&D , 1997 .
[17] Kim B. Clark,et al. Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of , 1990 .
[18] R. Rumelt,et al. Diversification strategy and profitability , 1982 .
[19] Spiros H. Martzoukos,et al. Real Option Games with R&D and Learning Spillovers , 2008 .
[20] Langche Zeng,et al. Analyzing Censored and Sample-Selected Data with Tobit and Heckit Models , 1999, Political Analysis.
[21] Luigi Orsenigo,et al. The emergence of biotechnology , 1989 .
[22] J. Schumpeter. Capitalism, Socialism and Democracy , 1943 .
[23] D. Schendel,et al. Strategic responses to technological threats , 1976 .
[24] Zubrod Cg. Historic milestones in curative chemotherapy , 1979 .
[25] Anand Swaminathan,et al. The Underemphasized Role of Established Firms as the Sources of Major Innovations , 1996 .
[26] H. P. Lang,et al. Drug Discovery And Development- Technology In Transition , 2009 .
[27] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[28] B. Silverman. Technological Resources and the Direction of Corporate Diversification: Toward an Integration of the Resource-Based View and Transaction Cost Economics , 1998 .
[29] Ferran A. Ayala. Combustion lean limits fundamentals and their application to a SI hydrogen-enhanced engine concept , 2006 .
[30] J. Barney. Firm Resources and Sustained Competitive Advantage , 1991 .
[31] Stuart J. H. Graham,et al. The Impact of Patenting on New Product Introductions in the Pharmaceutical Industry , 2007 .
[32] James M. Utterback,et al. Mastering the Dynamics of Innovation , 1996 .
[33] S. Winter. Understanding dynamic capabilities , 2003 .
[34] Cynthia A. Montgomery,et al. Diversified expansion by large established firms , 1991 .
[35] D. Teece. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .
[36] Karel Cool,et al. Asset stock accumulation and sustainability of competitive advantage , 1989 .
[37] B. Chabner,et al. Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.
[38] Steven Klepper,et al. Dominance by birthright: entry of prior radio producers and competitive ramifications in the U. S. , 2000 .
[39] Karel Cool,et al. Asset Stock Accumulation and the Sustainability of Competitive Advantage: Reply , 1989 .
[40] Igor H.Ansoff. Strategic Management , 1979 .
[41] Glenn R. Carroll,et al. The fates of De Novo and De Alio producers in the American Automobile Industry 1885–1981 , 2007 .
[42] P. Schoemaker,et al. Strategic assets and organizational rent , 1993 .
[43] Rebecca Henderson,et al. Sources of Industrial Leadership: The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional, and Organizational Change , 1999 .
[44] D. Teece,et al. DYNAMIC CAPABILITIES AND STRATEGIC MANAGEMENT , 1997 .
[45] Richard Makadok. Toward a synthesis of the resource‐based and dynamic‐capability views of rent creation , 2001 .
[46] Robert Weinberg,et al. Racing to the Beginning of the Road: The Search for the Origin of Cancer , 1996 .
[47] Mary Tripsas. Unraveling The Process Of Creative Destruction: Complementary Assets And Incumbent Survival In The Typesetter Industry , 1997 .
[48] M. Tushman,et al. Technological Discontinuities and Organizational Environments , 1986 .
[49] M. Lederman. The early history of radiotherapy: 1895-1939. , 1981, International journal of radiation oncology, biology, physics.
[50] A. Wells,et al. PLCγ contributes to metastasis of in situ-occurring mammary and prostate tumors , 2007, Oncogene.